Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277153 | 0.90 | F2 (0.51) | MRGPRX4KDM4EF2F10PRSS1 | |
| SCHEMBL2277407 | 0.80 | HDAC8 (0.61) | MRGPRX4TP53PKMNFKB1RAB9A | |
| SCHEMBL30954365 | 0.80 | THRB (0.58) | MRGPRX4RAB9ASMN1; SMN2THRBHCAR3 | |
| SCHEMBL29221030 | 0.80 | THRB (0.58) | MRGPRX4RAB9ASMN1; SMN2THRBHCAR3 | |
| SCHEMBL12403338 | 0.77 | CA1 (0.47) | MRGPRX4SMN1; SMN2MEP1B | |
| SCHEMBL31674610 | 0.76 | MRGPRX4 (0.71) | MRGPRX4TP53PKMNFKB1RAB9A | |
| SCHEMBL12373314 | 0.74 | CA1 (0.44) | MRGPRX4MEP1B | |
| SCHEMBL2275910 | 0.74 | PTGER4 (0.52) | MRGPRX4PTGER4PTGER2PPARGHCAR3 | |
| SCHEMBL2273602 | 0.73 | PLG (0.49) | — | |
| SCHEMBL1356949 | 0.72 | PLA2G10 (0.54) | RAB9AKDM4ETDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455516-B2 | HIV-1 fusion inhibitors and methods | TOURO UNIVERSITY (US) | 2013-06-04 | — | — | US | claimed |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | TOURO UNIVERSITY (US) | 2011-08-04 | — | — | US | claimed |
| US-8455516-B2 | HIV-1 fusion inhibitors and methods | TOURO UNIVERSITY (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | TOURO UNIVERSITY (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190343-A1 | HIV-1 FUSION INHIBITORS AND METHODS | FLI1, API5, MAVS | MRGPRX4 3121/4885TP53 1725/4885PKM 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.